EUVIMEDEUVIMED entdecken
Crossref

Development of a Gadolinium–Boron-Conjugated Albumin for MRI-Guided Neutron Capture Therapy

Satoshi Okada iD, Kai Nishimura, Qarri Ainaya, Kouichi Shiraishi, Sergey A Anufriev, Igor B Sivaev iD, Yoshinori Sakurai iD, Minoru Suzuki iD, Masayuki Yokoyama iD, Hiroyuki Nakamura iD

Molecular Pharmaceutics · 2023

DOI: 10.1021/acs.molpharmaceut.3c00726 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2023. Verfasst von Satoshi Okada und 9 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, 4259 Nagatsuta, Midori, Yokohama, Kanagaw…. Hauptthemen laut MEDLINE: Neoplasms, Neutron Capture Therapy, Boron Neutron Capture Therapy. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: Russian Foundation for Basic Research, Japan Society for the Promotion of Science, Japan Science and Technology Agency.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Noninvasive monitoring of boron agent biodistribution is required in advance of neutron capture therapy. In this study, we developed a gadolinium-boron-conjugated albumin (Gd-MID-BSA) for MRI-guided neutron capture therapy. Gd-MID-BSA was prepared by labeling bovine serum albumin with a maleimide-functionalized gadolinium complex and a maleimide-functionalized closo-dodecaborate orthogonally. The accumulation of Gd-MID-BSA in tumors in CT26 tumor-bearing mice reached a maximum at 24 h after the injection, as confirmed by T1-based MRI and biodistribution analysis using inductively coupled plasma optical emission spectrometry. The concentrations of boron and gadolinium in the tumors exceeded the thresholds required for boron neutron capture therapy (BNCT) and gadolinium neutron capture therapy (GdNCT), respectively. The boron concentration ratios of tumor to blood and tumor to normal tissues satisfied the clinical criteria, indicating the reduction of undesired nuclear reactions of endogenous nuclei. The molar ratio of boron to gadolinium in the tumor was close to that of Gd-MID-BSA, demonstrating that the accumulation of Gd-MID-BSA in the tumor can be evaluated by MRI. Thermal neutron irradiation with Gd-MID-BSA resulted in significant suppression of tumor growth compared to the group injected with a boron-conjugated albumin without gadolinium (MID-BSA). The neutron irradiation with Gd-MID-BSA did not cause apparent side effects. These results demonstrate that the conjugation of gadolinium and boron within the albumin molecule offers a novel strategy for enhancing the therapeutic effect of BNCT and the potential of MRI-guided neutron capture therapy as a promising treatment for malignant tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsNeutron Capture TherapyBoron Neutron Capture TherapyMiceAnimalsBoronGadoliniumTissue DistributionMagnetic Resonance ImagingMaleimides

Stichwörter der Autor:innen

MRIalbuminboron neutron capture therapycloso-dodecaborategadolinium contrast agents

Substanzen

BoronGadoliniumMaleimides

Autor:innen und Institutionen

  • Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, 4259 Nagatsuta, Midori, Yokohama, Kanagawa 226-8503, Japan.
  • School of Life Science and Technology, Tokyo Institute of Technology, 4259 Nagatsuta, Midori, Yokohama, Kanagawa 226-8503, Japan.
  • Division of Medical Engineering, Research Center for Medical Sciences, The Jikei University School of Medicine, 163-1 Kashiwashita, Kashiwa, Chiba 277-8567, Japan.
  • A.N. Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences, 28 Vavilov Str., 119334 Moscow, Russia.
  • Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2-1010 Asashiro-nishi, Kumatori, Sennan, Osaka 590-0494, Japan.

ORCID-Profile: Satoshi Okada, Igor B Sivaev, Yoshinori Sakurai, Minoru Suzuki, Masayuki Yokoyama, Hiroyuki Nakamura

Förderung

  • Russian Foundation for Basic Research
  • Japan Society for the Promotion of Science
  • Japan Science and Technology Agency

Zitieren

APA

Okada, S., Nishimura, K., Ainaya, Q., Shiraishi, K., Anufriev, S. A., Sivaev, I. B., Sakurai, Y., Suzuki, M., Yokoyama, M., & Nakamura, H. (2023). Development of a Gadolinium–Boron-Conjugated Albumin for MRI-Guided Neutron Capture Therapy. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.3c00726

Vancouver

Okada S, Nishimura K, Ainaya Q, Shiraishi K, Anufriev SA, Sivaev IB, et al. Development of a Gadolinium–Boron-Conjugated Albumin for MRI-Guided Neutron Capture Therapy. Molecular Pharmaceutics. 2023. doi:10.1021/acs.molpharmaceut.3c00726

BibTeX
@article{Okada2023,
  author = {Okada, Satoshi and Nishimura, Kai and Ainaya, Qarri and Shiraishi, Kouichi and Anufriev, Sergey A and Sivaev, Igor B and Sakurai, Yoshinori and Suzuki, Minoru and Yokoyama, Masayuki and Nakamura, Hiroyuki},
  title = {Development of a Gadolinium–Boron-Conjugated Albumin for MRI-Guided Neutron Capture Therapy},
  journal = {Molecular Pharmaceutics},
  year = {2023},
  doi = {10.1021/acs.molpharmaceut.3c00726}
}
Kostenlos starten →